Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphoma

弥漫性大B细胞淋巴瘤 淋巴瘤 医学 内科学 美罗华 免疫组织化学 肿瘤科 生发中心 血液学 病理 抗体 B细胞 免疫学
作者
Yasuto Naoi,Ryota Chijimatsu,Takahiro Urata,Kazutaka Sunami,Tamaki Imai,Yukifumi Nawa,Yasushi Hiramatsu,Kazuhiko Yamamoto,Soichiro Fujii,Isao Yoshida,Tomonori Yano,Kazuhiro Ikeuchi,Hiroki Kobayashi,Kazutoshi Tani,Yasuharu Sato,M. Boyle,Aixiang Jiang,Yoshinobu Maeda,David W. Scott,Daisuke Ennishi
出处
期刊:Hematological Oncology [Wiley]
卷期号:41 (S2): 301-302
标识
DOI:10.1002/hon.3164_210
摘要

Introduction: CD79B is a target of polatuzumab vedotin, an antibody–drug conjugate, which may improve the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL). However, the biological and clinical significance of CD79B protein and gene expression in DLBCL is largely unknown. Methods: We retrospectively analyzed de novo DLBCL patients, who were diagnosed and received rituximab-based immunochemotherapy from 2008 through 2018 in the Okayama Hematology Study Group from Japan. Immunohistochemistry (IHC) staining was performed using a CD79B antibody (AT107-2), and protein expression was assessed based on H-score according to a previous study (Sehn L et al. JCO 2020). We also performed gene expression profile-based cell-of-origin (COO) classification, including double-hit signature (DHITsig) which has been renamed to dark zone signature (DZsig) (Waleed A et al. Blood 2022), using the NanoString DLBCL90 assay. Results: CD79B IHC expression was evaluable in 602 cases. We idefined two groups according to median H-score of CD79B expression: CD79Bhigh and CD79Blow. The COO subtypes were assigned as follows: 308 patients (51%) with activated B-cell-like (ABC)-DLBCL, 196 (33%) with germinal center B-cell-like (GCB)-DLBCL, 32 (5%) with DZsig-pos DLBCL and 66 (11%) with unclassified (UNC). H-score of CD79B was the lowest in patients with ABC-DLBCL followed by GCB-DLBCL and DZsig-pos DLBCL in ascending order (Kruskal–Wallis test P < .00001; Figure A). Indeed, CD79Blow tumors were significantly enriched in ABC-DLBCL (57%) compared to GCB-DLBCL (40%) and DZsig-pos DLBCL (22%), respectively (both, P < .001). Consistently, using publicly available DLBCL datasets (Schmitz et al. NEJM 2018 and Ennishi et al. JCO 2019), we revealed that CD79B gene expression was the lowest in ABC-DLBCL compared to GCB- and DHITsig-DLBCL (Kruskal–Wallis test P = .01; Figure B and C). The association of CD79B expression with COO prompted us to evaluate CD79B expression in normal germinal center B cells. Notably single-cell transcriptomic analyses of six reactive lymphoid tissues from publicly available datasets revealed that the lowest expression of CD79B was found in plasmablasts followed by light zone B cells and dark zone B cells in ascending order (Kruskal–Wallis test P < .0001), supporting the differential expression of CD79Baccording to COO subtype. CD79Blow group had significantly shorter overall survival (OS) in the total DLBCL cohort (log-rank, P < .001) and within ABC-DLBCL (P = .001, Figure D and E). Moreover, CD79B protein expression was significantly associated with OS after adjusting for International Prognostic Index in the total cohort (Cox regression model; P< .001). Keywords: Aggressive B-cell non-Hodgkin lymphoma, Diagnostic and Prognostic Biomarkers Conflicts of interests pertinent to the abstract. K. Sunami Honoraria: Celgene, Sanofi, BMS, Ono, Janssen Research funding: Takeda, AbbVie, GSK, Chugai, Otsuka, MSD, Novartis, Astellas Amgen, Pfizer, Parexel, Kyowa Kirin, Symbio, Agios Y. Hiramatsu Honoraria: Chugai Pharmaceutical Co, Nippon Shinyaku Co, Bristol Myers Squibb, Sanofi K.K. I. Yoshida Honoraria: Kyowa Kirin, Chugai, Eisai, Jannsen, Nippon-shinyaku, Otsuka, Symbio, Takeda, Sumitomo Pharma, Meiji Research funding: Kyowa Kirin, Chugai Y. Maeda Research funding: Chugai, Nippon-shinyaku Other remuneration: Chugai, Eisai, Otsuka, Kyowa Kirin, Takeda D. W. Scott Consultant or advisory role: Abbvie, AstraZeneca, Janssen, Incyte Honoraria: AstraZeneca Research funding: Janssen, Roche/Genentech D. Ennishi Honoraria: Chugai, Eisai, Kyowa Kirin Research funding: Nipponshinyaku, Chugai
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋枫忆完成签到,获得积分10
1秒前
宋立发布了新的文献求助10
1秒前
孤独的AD钙完成签到,获得积分10
1秒前
2秒前
fang应助miao采纳,获得10
3秒前
星辰与月完成签到,获得积分10
3秒前
Pt-SACs发布了新的文献求助10
3秒前
安静无招完成签到 ,获得积分10
7秒前
lqphysics完成签到,获得积分10
8秒前
Jerry完成签到 ,获得积分10
8秒前
枕星发布了新的文献求助10
8秒前
全职法师刘海柱完成签到,获得积分10
10秒前
Umar完成签到,获得积分10
10秒前
accepted完成签到,获得积分10
11秒前
12秒前
Pt-SACs完成签到,获得积分10
13秒前
wgglegg完成签到 ,获得积分10
13秒前
饱满跳跳糖完成签到,获得积分10
13秒前
zhaoxiaonuan完成签到,获得积分10
13秒前
14秒前
赘婿应助2023204306324采纳,获得10
14秒前
英勇笑萍完成签到,获得积分10
15秒前
yar完成签到 ,获得积分10
16秒前
17秒前
伦语发布了新的文献求助10
17秒前
沉静怜蕾完成签到,获得积分10
17秒前
17秒前
欢呼白晴完成签到 ,获得积分10
18秒前
凉白开发布了新的文献求助10
18秒前
金扇扇完成签到 ,获得积分10
18秒前
Odyssey_Cheung完成签到,获得积分10
19秒前
JG完成签到,获得积分10
19秒前
明亮紫易完成签到,获得积分10
20秒前
张绪帆完成签到,获得积分10
20秒前
21秒前
龙眼完成签到,获得积分10
21秒前
clientprogram完成签到,获得积分0
21秒前
wendy发布了新的文献求助10
21秒前
量子星尘发布了新的文献求助10
22秒前
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029